Novartis tries to block generic versions of Gilenya, enforces new patent

Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UKIPO rejects Novartis’s TM opposition attempt

18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

More on this story

Big Pharma

UKIPO rejects Novartis’s TM opposition attempt

18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

More on this story

Big Pharma

UKIPO rejects Novartis’s TM opposition attempt

18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Novartis tries to block generic versions of Gilenya, enforces new patent

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features